Insider Trading Alert - CACI, GBX And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 13, 2014, 53 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $124.00 to $10,468,812.92.

Highlighted Stocks Traded by Insiders:

CACI International (CACI) - FREE Research Report

London J Phillip who is Director at CACI International sold 15,577 shares at $75.05 on Jan. 13, 2014. Following this transaction, the Director owned 83,033 shares meaning that the stake was reduced by 15.8% with the 15,577-share transaction.

Bradford Gregory R who is Chief Executive, CACI Limited at CACI International sold 5,900 shares at $76.28 on Jan. 13, 2014. Following this transaction, the Chief Executive, CACI Limited owned 42,990 shares meaning that the stake was reduced by 12.07% with the 5,900-share transaction.

The shares most recently traded at $78.14, up $1.86, or 2.39% since the insider transaction. Historical insider transactions for CACI International go as follows:

  • 4-Week # shares sold: 500
  • 12-Week # shares sold: 23,478
  • 24-Week # shares sold: 24,453

The average volume for CACI International has been 255,900 shares per day over the past 30 days. CACI International has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are up 6.5% year-to-date as of the close of trading on Monday.

CACI International Inc., together with its subsidiaries, provides information solutions and services to the U.S. federal government and commercial markets in North America and internationally. The company has a P/E ratio of 12.7. Currently there are 3 analysts that rate CACI International a buy, 3 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CACI - FREE

TheStreet Quant Ratings rates CACI International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CACI International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Greenbrier Companies (GBX) - FREE Research Report

Centurion Alejandro who is Pres GMO CEO Gunderson at Greenbrier Companies sold 3,000 shares at $34.66 on Jan. 13, 2014. Following this transaction, the Pres GMO CEO Gunderson owned 44,291 shares meaning that the stake was reduced by 6.34% with the 3,000-share transaction.

The shares most recently traded at $34.74, up $0.08, or 0.22% since the insider transaction. Historical insider transactions for Greenbrier Companies go as follows:

  • 4-Week # shares sold: 27
  • 12-Week # shares sold: 36,714
  • 24-Week # shares sold: 37,149

The average volume for Greenbrier Companies has been 384,900 shares per day over the past 30 days. Greenbrier Companies has a market cap of $970.2 million and is part of the services sector and transportation industry. Shares are up 5.66% year-to-date as of the close of trading on Monday.

The Greenbrier Companies, Inc. designs, manufactures, and markets railroad freight car equipment in North America and Europe. The stock currently has a dividend yield of 3.44%. Currently there are 9 analysts that rate Greenbrier Companies a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GBX - FREE

TheStreet Quant Ratings rates Greenbrier Companies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and poor profit margins. Get the full Greenbrier Companies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 8,200 shares at $8.59 on Jan. 13, 2014. Following this transaction, the CEO & Chairman owned 137.8 million shares meaning that the stake was reduced by 0.01% with the 8,200-share transaction.

The shares most recently traded at $8.86, up $0.27, or 3.07% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 5.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 4.27% year-to-date as of the close of trading on Monday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Stocks Lose Steam as Yields Hover Near 3% Threshold

Stocks Lose Steam as Yields Hover Near 3% Threshold

Here Are the 3 Biggest Market Movers Monday

Here Are the 3 Biggest Market Movers Monday

Learn Options Trading from the Najarian Brothers, the Best in the Business

Learn Options Trading from the Najarian Brothers, the Best in the Business

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)